Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria

Fig. 1Fig. 1

Heat maps. Heat maps illustrate group differences for ravulizumab (a) and eculizumab (b) using Cohen’s d effect size computed from aggregated means and standard deviations by age and gender groupings. Conditional formatting illustrates effect-size magnitude with a more saturated color reflecting larger effect size. Since all of the differences were in the direction of PNH group scoring better than the general population (i.e., higher on function/global QOL scales, lower on symptom scales/items), only one color is used for the conditional formatting. Figure a includes people with PNH on ravulizumab after 26 weeks either during the randomized period or during the extension-trial period. This meant assessment at 52 weeks for patients who had eculizumab for 26 weeks and then had ravulizumab for 26 weeks. Includes Trial 301 (N = 242) and 302 (N = 185). Figure b includes people with PNH who had been on eculizumab for 26 weeks. All these patients' assessments were made during the randomized period. Includes Trial 301 (N = 118) and 302 (N = 95)

Back to article page